Infliximab treatment of glycogenosis Ib with Crohn's-like enterocolitis: A case report
作者机构：Gastroenterology DepartmentCapital Institute of PediatricsBeijing 100020China Pathology DepartmentCapital Institute of PediatricsBeijing 100020China
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2021年第9卷第19期
页 面：5280-5286页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority No.XXZ0505
主 题：Crohn’s disease Glycogen storage disease type I Treatment Infliximab Case report
摘 要：BACKGROUND Glycogen storage disease type Ib(GSD-Ib)is a glycogen metabolism disorder that leads to the manifestations of inflammatory bowel disease(IBD),especially Crohn’s disease(CD)-like *** biological agents are effective for treating CD,their application in the treatment of GSD-Ib with CD-like colitis has been rarely *** SUMMARY A 13-year-old Han male was diagnosed with GSD-Ib with *** patient was treated with granulocyte colony-stimulating *** he had symptoms of CD-like colitis,he was continuously pumped with enteral nutrition and administered oral mesalazine for 2 wk;however,the symptoms did not improve ***,infliximab(IFX)was ***,the patient has been followed up for 1 year,and no clinical manifestations have been *** 6 mo of treatment(fifth IFX treatment),the disease activity index and all inflammatory indexes decreased,and a review of the colonoscopy data showed that the ulcers appeared *** In this study,the patient was successfully treated with *** cases of GSD-Ib,IBD should be highly considered.
维普期刊数据库